



Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference

November 1, 2022

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Nov. 1, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2022 Jefferies London Healthcare Conference being held from November 15-17, 2022 in London.

Details of the event are as follows:

Date: Tuesday, November 15, 2022

Time: 7:25 a.m. GMT

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio's website at <http://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAbs), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20221101005354/en/>

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.